Concepedia

David Elkayam

DE

4

Publications

377

Citations

4

H-Index

2012

Active since

Affiliations

Hull York Medical School(Current)

David Elkayam is an author at Hull York Medical School specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2012–2024

4

Publications

4

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 216 citations · Full text

, , +6

NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis

Donald A. Leopold, David Elkayam, John Messina et al. · Journal of Allergy and Clinical Immunology · 2018 · 99 citations · Full text

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

Richard L. Wasserman, Joseph A. Church, Mark R. Stein et al. · Journal of Clinical Immunology · 2012 · 50 citations · Full text

Cough frequency has a high daily variation in patients with chronic cough

Alyn H. Morice, Mitja Alge, Laura Kuett et al. · ERJ Open Research · 2024 · 12 citations · Full text

Rows per page

1–4 of 4